

24<sup>th</sup> August, 2021

<b>To,</b> <b>Department of Corporate Services</b> <b>Bombay Stock Exchange Ltd.</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.	<b>To,</b> <b>The Manager,</b> <b>Listing Department,</b> <b>National Stock Exchange of India Ltd.</b> “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.
<b>Ref.: Scrip Code No. : 540701</b>	<b>Ref. : (i) Symbol – DCAL</b> <b>(ii) Series – EQ</b>

**Sub.: Announcement: Company’s wholly-owned subsidiary viz. CARBOGEN AMCIS AG has signed a co-investment agreement of more than CHF 4 million with a long-standing Europe-based client**

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that Company’s wholly owned subsidiary namely CARBOGEN AMCIS AG., Switzerland has entered into a co-investment agreement of more than CHF 4 million with a Europe based key client. The agreement provides for additional process capabilities and capacities to facilitate the manufacture of the customer’s commercial product and follows a previous investment of CHF 6 million.

In this regard, please find enclosed herewith Press Release on the captioned subject.

Kindly take the same on your record.

Thanking You,

Yours faithfully,  
**For, Dishman Carbogen Amcis Limited**

  
**Shrima Dave**  
**Company Secretary**



Encl.: As above

**Dishman Carbogen Amcis Limited**

Regd. Off.: DISHMAN CORPORATE HOUSE  
Iscon-Bopal Road, Ambli, Ahmedabad-380 058, Gujarat, India.  
Phone : +91 (0) 2717 420102 / 2717 420124

E-mail : [dcal@dishmangroup.com](mailto:dcal@dishmangroup.com)  
Website : [www.dishmangroup.com](http://www.dishmangroup.com)

Government Recognised Export House  
CIN No. : L74900GJ2007PLC051338

## PRESS RELEASE

---

**DISHMAN CARBOGEN AMCIS LIMITED announces that its subsidiary, CARBOGEN AMCIS AG, has entered into a co-investment agreement of more than CHF 4 million with a long-standing Europe-based client**

**Ahmedabad, India (August Day, 2021) — Switzerland-based Company’s subsidiary, CARBOGEN AMCIS AG., a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the signing of a co- investment agreement with one of its key European customers. The agreement provides for additional process capabilities and capacities to facilitate the manufacture of the customer’s commercial product and follows a previous investment of CHF 6 million.**

The co-investment totals CHF 4 million and will be focussed on expanding capacities to support the market introduction of the customer’s lead compound. The investment at the CARBOGEN AMCIS AG. Neuland location includes the addition of a medium pressure chromatography column (200L), a preparative 20 cm HPLC system and short path distillation equipment.

“We are committed to providing our customers with the best technologies and this investment will allow our client to benefit from state-of-the-art equipment that enables expanded manufacturing capacity to commercialization scale-up, and getting a much-needed drug to patients,” said Stephan Fritschi, VP operations, CARBOGEN AMCIS AG.

This agreement follows an earlier CHF 6 million investment made in 2017 by the same customer at the CARBOGEN AMCIS AG.’ Neuland location.

The collaboration between the two companies spans more than 10 years and started during the project’s pre-clinical development stage. “We have supported our client from the early stages of pre-clinical development all the way through to routine commercial manufacture. We are proud to be part of our customer’s successful journey towards product commercialization and this co-investment is the latest milestone in our long-standing partnership,” said Pascal Villemagne, VP sales and marketing, CARBOGEN AMCIS AG.

CARBOGEN AMCIS AG.’ Neuland location specializes in early phase development and rapid kg API supply to GMPs. Its strong analytical capabilities and crystallization lab can serve up numerous customers simultaneously. The recent chromatography equipment addition reinforces the extensive offerings available at this site.

The equipment is expected to be ready for production by Q1 2023.

\*\*\*\*

CARBOGEN AMCIS AG. ([www.carbogen-amcis.com](http://www.carbogen-amcis.com)) is a leading service provider offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Our integrated services and innovative chemistry solutions support timely and safe drug development, allowing customers to better optimize available resources. CARBOGEN AMCIS AG. is a wholly owned subsidiary of Dishman Carbogen Amcis Limited, Ahmedabad, India.

Dishman Carbogen Amcis Limited ([www.imdcal.com](http://www.imdcal.com)) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and in India.